Optimizing response to phosphodiesterase type 5 inhibitors

Current Sexual Health Reports

Volumn 4, Issue 1, 2007, Pages 1-6

  Sadovsky, Richard ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADJUVANT THERAPY; ANAMNESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FOLLOW UP; FOOD DRUG INTERACTION; HUMAN; INTERVIEW; MALE; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33947379186     PISSN: 15483584     EISSN: 15483592     Source Type: Journal    
DOI: 10.1007/BF02938324     Document Type: Review

References (47)

1. Hellstrom WJG: Management recommendations for family physicians. J Fam Pract 2005, 54(Suppl):32-40.
2. Jiann BP, Yu CC, Su CC, Tsai JY: Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006, 18:146-149.
3. Hackett GI: Patient preferences in the treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005, 7:57-65. This is an excellent discussion of important educational points that are needed to optimize treatment success.
4. Souverein PC, Egberts AC, Meuleman EJ, et al.: Incidence and determinants of sildenafil (dis)continuation: the Dutch cohorts of sildenafil users. Int J Impot Res 2002, 14:259-265.
5. Vickers MA, Satyanarayana R: Phosphosdiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002, 14:466-471.
6. Kostis JB, Jackson G, Rosen R, et al.: Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005:96:313-321. This article is an up-to-date summary of cardiovascular issues that need to be considered when treating ED with phosphodiesterase type 5 inhibitors.
7. Gonzalgo ML, Brotzman M, Trock BJ, et al.: Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003, 170:503-506.
8. Althof SE: When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002, 14(Suppl 1):S99-S104.
9. Sadovsky R, Althof S: Men's sexual issues. In Clinics in Family Practice: Sexual Health. Edited by Nusbaum M. Oxford: W.B. Saunders Company; 2004:863-915. This chapter provides a good discussion on how to evaluate men with sexual problems and how to assure that the primary problem is erectile dysfunction.
10. Sadovsky R. Asking the questions and offering solutions: the ongoing dialogue between the primary care physician and the patient with erectile dysfunction. Rev Urol 2003, 5(Suppl 7):S35-S48.
11. Montorsi F, Burnett AL: Erectile dysfunction after radical prostatectomy. BJU Int 2004, 93:1-2.
12. Hatzimouratidis K, Hatzichristou DG: A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005, 65:1621-1650. This thorough review compares the three available phosphodiesterase type 5 inhibitors that are available to treat erectile dysfunction.
13. Stroberg P, Murphy A, Costigan T: Switching patients with erectile dysjunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003, 25:2724-2737.
14. Hedelin H, Stroberg P: Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. Drugs 2005, 65:2245-2251.
15. Mulhall JP, Montorsi F: Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006, 49:30-37.
16. McMahon CG: High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res 2002, 14:533-538.
17. Atiemo HO, Szostak MJ, Sklar GN: Salvage of sildenafil failures referred from primary care physicians. J Urol 2003, 170:2356-2358.
18. McCullough AR, Barada JH, Fawzy A, et al.: Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002, 60:28-38.
19. Hatzichristou D, Cuzin B, Martin-Morales A, et al.: Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005, 2:109-116.
20. Yang BK, Donatucci CF. Drugs that affect male sexual function. In Male Sexual Function. Edited by Mulcahy JJ. Totowa: Humana Press; 2006:155-194.
21. Lue TF: Erectile dysfunction. N Engl J Med 2000, 342:1802-1813.
22. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41-57.
23. Lewis R, Bennett CJ, Borkon WD, et al.: Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 2001, 57:12-17.
24. Shabsigh R: Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005, 2:785-792.
25. Montorsi F, Oettel M: Testosterone and sleep-related erections: an overview*;. J Sex Med 2005:771-784.
26. Morelli A, Filippi S, Mancina R, et al.: Androgens regulate phosphodiesterase type 5 expression and functional activity in corpus cavernosa. Endocrinology 2004, 145:2253-2263.
27. Shabsigh R: Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005, 2:758-792.
28. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004, 172:658-663.
29. Chen J, Sofer M, Kaver I, et al.: Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol 2004, 171:292-295.
30. Raina R, Agarwal A, Allamaneni SS, et al.: Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 2005, 65:360-364.
31. Raina R, Nandipati KC, Agarwal A, et al.: Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005, 26:757-760.
32. Gutierrez P, Hernandez P, Mas M: Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res 2005, 17:354-358.
33. Ichikawa T, Takao A, Manabe D, et al.: The female partner's satisfaction with sildenafil citrate treatment of erectile dysfunction. Int J Urol 2004, 11:755-762.
34. Rosen RC: Psychogenic erectile dysfunction. Classification and management. Urol Clin North Am 2001, 28:269-278.
35. Phelps JS, Jain A, Monga M: The PsychoedPlusMed approach to erectile dysfunction treatment: the impact of combining a psychoeducational intervention with sildenafil. J Sex Marit Ther 2004, 30:305-314.
36. Althof SE, Wieder M: Psychotherapy for erectile dysfunction: now more relevant than ever. Endocrine 2004, 23:131-134.
37. Esposito K, Giugliano F, Di Palo C, et al.: Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291:2978-2984. This article presents good evidence that weight loss can improve erectile function for men who are obese and have ED.
38. Derby CA, Mohr BA, Goldstein I, et al.: Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000, 56:302-306.
39. Jackson G. Erectile dysfunction: a management algorithm [editorial]. Int J Clin Pract 2004, 58:733-734.
40. Fabbri A, Caprio M, Aversa A: Pathology of erection. J Endocrinol Invest 2003, 26(Suppl 3):87-90.
41. Lewis RW, Fugl-Meyer KS, Bosch R, et al: Definitions, classification, and epidemiology of sexual dysfunction. In Sexual Medicine: Sexual Dysfunctions in Men and Women. Edited by Lue TF, Basson R, Rosen R, et al.: Paris: Health Publications; 2004:39-72.
42. Derby CA, Mohr BA, Goldstein I, et al.: Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000, 56:302-306.
43. Pinnock CB, Stapleton AM, Marshal VR: Erectile dysfunction in the community: a prevalence study. Med J Aust 1999, 171:353-357.
44. Guay AT, Perez JB, Jacobson J, Newton RA: Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001, 22:793-797.
45. Romeo JH, Seftel AD, Madhun ZT, Aron DC: Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000, 163:788-791.
46. Carson CC, Lue TF: Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005, 95:257-280.
47. Rutchik SD, Baudiere M, Wade M, et al.: Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. Urology 2001, 57:146-150.